When will daprostat be launched in China?

Daprodustat (Daprodustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by GlaxoSmithKline (GSK) for the treatment of anemia caused by chronic kidney disease (CKD). This drug promotes the production of endogenous erythropoietin by stabilizing hypoxia-inducible factor, thereby stimulating red blood cell production and improving anemia symptoms. Currently, daprostat has been approved in Japan and the United States, but it is not yet available in mainland China.

In Japan, daprostat was approved under the trade name Duvroq in June 2020 for the treatment of patients with anemia caused by CKD. In the United States, daprostat, branded as Jesduvroq, was approved by the U.S. Food and Drug Administration (FDA) on February 1, 2023, and is suitable for adult CKD patients who have received dialysis for at least four months. There is currently no official approval information regarding the listing of daprostat in China. Although GSK is actively advancing clinical trials and marketing applications for daplestat globally, the drug registration and approval process in mainland China may take longer. In addition, daprostat has not yet been included in China's medical insurance catalog, so its price information is unclear.

It should be noted that daplestat may cause some adverse reactions during treatment, such as hypertension, thrombotic vascular events, abdominal pain, dizziness, and allergic reactions. Therefore, when using this drug, it should be done under the guidance of a doctor, and relevant indicators should be monitored regularly.

In short, as a new oral treatment for CKD anemiadaprostat has been approved in Japan and the United States, but has not yet been launched in mainland China. When considering using this drug, patients should pay close attention to its launch progress in China and conduct treatment under the guidance of professional doctors.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat